G. Mani Subramanian, M.D., Ph.D.

Dr. Subramanian is the founding CEO of The Liver Company (TLC) and a Venture Partner at Samsara BioCapital. He was previously at Gilead Sciences from 2011-2020, where he was the Senior Vice President and Therapeutic Area Head for Liver Diseases. He was responsible for the developing and implementing the R&D vision for liver diseases, which lead to the approval of compounds for the treatment of patients with viral hepatitis (Sovaldi®, Harvoni®, Epclusa®, Vosevi®, Vemlidy®), and a compound portfolio in non-alcoholic steatohepatitis, cholestatic liver disease, and alcoholic hepatitis. From 2002-2010, he was at Human Genome Sciences where he led clinical programs of albumin-fusion proteins and monoclonal antibodies for immunology and infectious disease indications, notably clinical development of Zalbin® for HCV, and ABthrax® for anthrax. He started his biotechnology career at Celera Genomics in 2000 and was a major contributor to the proteome annotation of the human, mouse, and anopheles genome sequencing efforts. He has over 160 scientific publications including in NEJM, Lancet, JAMA, Science & Nature. Dr. Subramanian received his medical degree at the Armed Forces Medical College, India, completed his Ph.D. (Immunology & Microbiology) at the University at Michigan, Ann Arbor, followed by residency in Internal Medicine at University Hospitals of Cleveland, Case Western Reserve University, and fellowship in Infectious Diseases, with post-doctoral research at the National Institute of Allergy and Infectious Diseases, NIH.